Study on Selinexor, Venetoclax, and Dexamethasone for Treating Relapsed or Refractory Multiple Myeloma with t(11;14) Mutation

Inclusion Criteria

• Must have a confirmed diagnosis of multiple myeloma with specific criteria, such as certain levels of proteins in the blood or bone marrow, or specific symptoms like anemia or bone lesions.
• Must have a specific genetic mutation called t(11;14) in their myeloma cells, confirmed by a lab test.
• Must have relapsed or refractory multiple myeloma, meaning the cancer has returned or not responded to at least two previous treatments.
• Must have measurable disease based on specific medical guidelines.
• Must be 18 years or older.
• Must have a performance status that allows for daily activities with some limitations.
• Must have adequate organ function based on specific blood test results.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study.
• Must be willing to provide informed consent and comply with study procedures.

Exclusion Criteria

• Have previously received selinexor or similar drugs.
• Have any medical condition that could interfere with the study, such as uncontrolled high blood pressure or diabetes.
• Have an active infection requiring treatment within a week before starting the study.
• Have an allergy or intolerance to steroids.
• Are pregnant or breastfeeding.
• Have unstable heart conditions or recent heart attack.
• Have active hepatitis B or untreated hepatitis C, unless under specific conditions.
• Have difficulty swallowing pills or any condition affecting drug absorption.
• Are unable or unwilling to take supportive medications for nausea or appetite.
• Have any serious psychiatric or medical conditions that could interfere with the study.
• Have any contraindications to the study drugs or required treatments.
• Are unable or unwilling to comply with the study protocol.